妊娠期破伤风、白喉和百日咳疫苗接种的安全性:一项系统综述
该系统综述纳入21项研究,评估妊娠期接种含百日咳疫苗抗原的联合疫苗后孕妇、胎儿和婴儿的结局。证据提示妊娠中晚期接种联合Tdap疫苗与胎儿或新生儿临床显著伤害无关;孕妇就医事件在接种组与未接种组相似。
要点
- 妊娠中晚期接种联合Tdap疫苗与胎儿或新生儿临床显著伤害无关。
- 早产、小于胎龄儿、死产、新生儿死亡、低出生体重和先天畸形的点估计值均低于1.0,但95%CI下限均小于1.0。
- 孕妇就医事件在接种组与未接种组之间相似。
核心结论
- 证据提示妊娠中晚期接种联合Tdap疫苗与胎儿或新生儿临床显著伤害无关。
- 孕妇就医事件在接种组与未接种组之间相似。
研究设计与样本
- 系统综述,检索PubMed、EMBASE、拉丁美洲和加勒比健康科学文献、ClinicalTrials.gov、Cochrane图书馆和世界卫生组织数据库(从建库至2016年5月5日)。
- 纳入报告孕妇、胎儿或婴儿产前暴露于单价或联合破伤风类毒素、减量白喉类毒素和无细胞百日咳(Tdap)疫苗或灭活脊髓灰质炎疫苗后结局的研究。
- 共纳入21项研究,主要为回顾性观察性研究,总体偏倚风险高。
主要发现
- 早产(妊娠不足37周)的点估计值范围为0.47至1.50。
- 小于胎龄儿(出生体重低于第10百分位)的点估计值范围为0.65至1.00。
- 死产的点估计值范围为0.36至0.85。
- 新生儿死亡的点估计值范围为0.16至1.00。
- 低出生体重(低于2500克)的点估计值范围为0.76至1.20;先天畸形的点估计值范围为0.20至0.91;所有95%CI下限均小于1.0。
关键数值与推荐
- 三项评估接种后绒毛膜羊膜炎的回顾性研究中,一项显示小幅但具有统计学意义的增加。
- 产前破伤风类毒素疫苗接种后所有畸形的点估计值范围为1.20至1.60,95%CI跨越1.0。
- 客观发热率低,为3%或以下;更常见的全身事件包括头痛、不适和肌痛。
临床怎么用
- 原文未据此给出推荐。
局限性
- 存在显著的临床和方法学异质性,主要来自回顾性观察性研究,总体偏倚风险高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess antenatal, birth, and infant outcomes for pregnant women, fetuses, and infants after antenatal vaccination with any antigen present in combination pertussis vaccines. DATA SOURCES: PubMed, EMBASE, Literature in the Health Sciences in Latin America and the Caribbean, ClinicalTrials.gov, Cochrane Library, and World Health Organization (inception to May 5, 2016). METHODS OF STUDY SELECTION: Studies reporting outcomes for pregnant women, their fetus, or infant after antenatal exposure to either monovalent or combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) or inactivated polio vaccines were considered for inclusion. RESULTS: A total of 21 studies were included in this review. Point estimates ranged from 0.47 to 1.50 for preterm birth (less than 37 weeks of gestation), 0.65-1.00 for small for gestational age (birth weight less than the 10th percentile), 0.36-0.85 for stillbirth, 0.16-1.00 for neonatal death, 0.76-1.20 for low birth weight (less than 2,500 g), and 0.20-0.91 for congenital anomalies. All lower 95% confidence intervals (CIs) were less than 1.0. Of three retrospective studies assessing chorioamnionitis after vaccination, one showed a small but statistically significant increase. Point estimates for all anomalies after antenatal tetanus toxoid vaccination ranged from 1.20 to 1.60 and had 95% CIs that crossed 1.0. There was substantial clinical and methodologic heterogeneity from mainly retrospective observational studies with an overall high risk of bias. Objective rates of fever were low, 3% or below, and more common systemic events observed included headache, malaise, and myalgia. CONCLUSION: Evidence suggests that antenatal combined Tdap administered during the second or third trimester of pregnancy is not associated with clinically significant harms for the fetus or neonate. Medically attended events in pregnant women are similar between vaccinated and unvaccinated groups.
引用
- McMillan M, Clarke M, Parrella A, et al. Safety of Tetanus, Diphtheria, and Pertussis Vaccination During Pregnancy: A Systematic Review. Obstet Gynecol. 2017. PMID: 28178054. doi:10.1097/AOG.0000000000001888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。